Raltitrexed in mesothelioma

Expert Review of Anticancer Therapy

Volumn 11, Issue 10, 2011, Pages 1481-1490

  Surmont, Veerle F ^a   Van Meerbeeck, Jan P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

mesothelioma; quality of life; raltitrexed; Tomudex ; TS inhibitor; ZD1694

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; METHOTREXATE; OXALIPLATIN; PEMETREXED; PRALATREXATE; RALTITREXED; THYMIDINE; THYMIDYLATE SYNTHASE;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALAISE; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PARESTHESIA; PATIENT CARE; PLEURA MESOTHELIOMA; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR CLASSIFICATION; VOMITING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 80054770327     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.136     Document Type: Article

References (57)

1. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy for malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117(1), 54-63 (1999).
2. Flores RM, Krug LM, Rosenzweig KE et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a Phase II trial. J Thorac. Oncol. 1(4), 289-295 (2006). (Pubitemid 47163979)
3. Nakas A, Martin-Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 33(1), 83-88 (2008). (Pubitemid 350284603)
4. Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur. J. Cardiothorac. Surg. 20(6), 1117-1121 (2001). (Pubitemid 33051079)
5. Ung YC, Yu E, Falkson C et al. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother. Oncol. 80(1), 13-18 (2006). (Pubitemid 44205305)
6. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin. Oncol. 26(2), 68-73 (1999). (Pubitemid 29218031)
7. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin. Oncol. 26(2), 42-47 (1999). (Pubitemid 29218027)
8. Moran RG. Roles of folylpoly-g glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin. Oncol. 26(2), 24-32 (1999). (Pubitemid 29218024)
9. Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo [2, 3-D] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57, 1116-1123 (1997). (Pubitemid 27138611)
10. Vogelzang N, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003). (Pubitemid 46606305)
11. Hazarika M, White RM Jr, Booth BP et al. Pemetrexed in malignant pleural mesothelioma. Clin. Cancer Res. 11(3), 982-992 (2005). (Pubitemid 40175745)
12. Hughes AN, Raf I, Griffn MJ et al. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. Clin. Cancer Res. 5(1), 111-118 (1999). (Pubitemid 29045183)
13. Gish RG, Porta C, Lazar L et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 25(21), 3069-3075 (2007).
14. Krug LM, Heelan RT, Kris MG, Venkatraman E, Sirotnak FM. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J. Thorac. Oncol. 2(4), 317-320 (2007). (Pubitemid 47181715)
15. Webber S, Bartlett CA, Boritzki TJ et al. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother. Pharmacol. 37(6), 509-517 (1996). (Pubitemid 26080147)
16. Jackman AL, Judson IR. The new generation of thymidylate synthase inhibitors in clincial study. Expert Opin. Invest. Drugs 5, 719-736 (1996).
17. Rustum YM, Harstrick A, Cao S et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15(1), 389-400(1997). (Pubitemid 27020596)
18. Touroutoglou N, Pazdur R. Thymidylate synthase inhibitors. Clin. Cancer Res. 2, 227-243 (1996). (Pubitemid 26075633)
19. Cassidy J. Thymidylate synthase inhibitors in colorectal cancer. Semin. Oncol. 27(5), 83-87 (2000).
20. Judson IR. Tomudex (raltitrexed) development: preclinical, Phase I and II studies. Anticancer Drugs 8(2), S5-S9 (1997).
21. 10-substituted-5-8-dideazafolates. Adv. Enzyme Regul. 31, 13-27 (1991).
22. Jackman AL, Taylor GA, Gibson W et al. ICI D1694, a quinazoline antifolate thymidyltae inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 51(20), 5579-5586 (1991).
23. Jackman AL, Farrugia DC, Gibson W et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer 31, 1277-1285 (1995).
24. Jackman AL, Gibson W, Brown M, Kimbell R, Boyle FT. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv. Exp. Med. Biol. 339, 265-276 (1993). (Pubitemid 24073371)
25. Ward WH, Kimbell R, Jackman AL. Kinetic characteristics of ICI D1694: quinazoline antifolate which inhibits thymidylate synthase. Biochem. Pharmacol. 43(9), 2029-2031 (1992).
26. Aherne GW, Farrugia DC, Ward E, Sutcliffe F, Jackman AL. ZD1694 (Tomudex) and polyglutamate levels in mouse plasma and tissues measured by radio-immunoassay (RIA) and the effect of leucovorin (LV). Proc. Am. Cancer Res. 36, 376 (1995).
27. Jackman AL, Gibson W. Polyglutamation of the thymidylate synthase inhibitor, ZD1694 (Tomudex) in normal mouse tissues. Proc. Am. Assoc. Cancer Res. 36, 377 (1995).
28. Kimbell R, Jackman AL, Boyle FT. The duration of the inhibition of thymidylate synthase in intact L1210 cells exposed to different classes of quinazoline analogues. In: Chemistry and Biology of Pteridines and Folates. Advances in Experimental Medicines and Biology. Ayling JE, Nair MG, Baugh CM (Eds). Plenum Press, NY, USA 338, 597-600 (1993). (Pubitemid 23340658)
29. Jodrell DI, Newell DR, Gibson W, Hughes LR, Calvert AH. The pharmacokinetics of the quinazoline antifolate ICI 1694 in mice and rats. Cancer Chemother. Pharmacol. 28(5), 331-338 (1991).
30. Jodrell DI, Newell DR, Calvete JA, Stephens TC, Calvert AH. Pharmacokinetic and toxicity studies with the novel quinazoline thymidylate synthase (TS) inhibitor, D1694. Proc. Am. Assoc. Cancer Res. 31, 341 (1991).
31. Clarke SJ, Hanwell J, De Boer M et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J. Clin. Oncol. 14(5), 1495-1503 (1996). (Pubitemid 26134205)
32. Judson IR, Aherne GW, Maughan T et al. Pharmacokinetic studies with Tomudex (ZD 1694) Ann. Oncol. 7(88) (1996) (Abstract 304).
33. Judson IR. Tomudex (raltitrexed) development-preclinical, Phase I and II studies. Anticancer Drugs 8, S5-S9 (1997).
34. Sorensen JM, Jordon E, Grem JL et al Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann. Oncol. 5, 132 (1994).
35. Fizazi K, Ducreux M, Ruffé P et al. A Phase I, dose-fnding and pharmacokinetic study of raltitrexed ('Tomudex') combined with oxaliplatin in patients with advanced cancer. J. Clin. Oncol. 18(11), 2293-2300 (2000). (Pubitemid 30350222)
36. Baas P, Ardizzoni A, Grossi F et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC Phase II study (08992). Eur. J. Cancer 39(3), 353-357 (2003). (Pubitemid 36140053)
37. Fizazi K, Viala J, Daniel C et al. Raltitrexed ('Tomudex') and oxaliplatin: an active out-patient regimen in malignant mesothelioma. Eur. J. Cancer 35(4), S252 (1999).
38. Rothenberg ML, Moore MJ, Cripps MC et al. A Phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann. Oncol. 7, 347-353 (1996). (Pubitemid 26246785)
39. Porta C, Zimatore M, Bonomi L et al Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48, 429-434 (2005). (Pubitemid 40693630)
40. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23(28), 6881-6889 (2005).
41. Bottomley A, Gaafar R, Manegold C et al Short-term treatment-related symptoms and quality of life: results from an international randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J. Clin. Oncol. 24(9), 1435-1442 (2006). (Pubitemid 46622010)
42. Woods BS, Paracha N, Scott DA, Thatcher N. Raltitrexed plus cisplatin is cost effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer (2011) (In Press).
43. Faccihini T, Genet D, Berdah JF. Raltitrexed ('Tomudex') has a manageable toxicity profle in elderly patients with metastatic colorectal cancer: fnal analysis of a multicentre study. Proc. Am. Soc. Clin. Oncol. 19, 298a (2000).
44. Holbrook AM, Pereira JA, Labiris R. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 165, 1095-1106 (2005). (Pubitemid 40720733)
45. Van Cutsem E. Raltitrexed (Tomudex) Expert Opin. Invest. Drugs 7(5), 823-834 (1998).
46. Wilson KS, Malfair Taylor SC. Raltitrexed: optimism and reality. Expert Opin. Drug Metab. Toxicol. 5(11), 1447-1454 (2009).
47. Woll PJ, Basser R, Le Chevalier T et al. Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. Br. J. Cancer 76(2), 264-265 (1997). (Pubitemid 27279670)
48. Scagliotti GV, Park K, Patil S et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-beneft analysis of a large Phase III study. Eur. J. Cancer 45 (13), 2298-2303 (2009).
49. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7), 1589-1596 (2006). (Pubitemid 44546920)
50. Sørensen JB, Frank H, Palshof T Cisplatin and vinorelbine frst-line chemotherapy in non-resectable malignant pleural mesothelioma. Br. J. Cancer 99(1), 44-50 (2008). (Pubitemid 351920221)
51. Bech C, Sørensen JB. Chemotherapy induced pathological complete response in malignant pleural mesothelioma: a review and case report. J. Thorac. Oncol. 5(5), 735-740 (2010).
52. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38(2), 111-121 (2002). (Pubitemid 35157753)
53. Hillerdal G, Sorensen JB, Sundström S, Vikström A, Hjerpe A. Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study. Clin. Respir. J. 2(2), 80-85 (2008).
54. Talbot DC, Margery J, Dabouis G et al. Phase II study of vinfunine in malignant pleural mesothelioma. J. Clin. Oncol. 25(30), 4751-4756 (2007). (Pubitemid 350086477)
55. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23(9), 2020-2027 (2005). (Pubitemid 46211382)
56. Righi L, Papotti MG, Ceppi P et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J. Clin. Oncol. 28(9), 1534-1539 (2010).
57. Van Meerbeeck JP, Damhuis RAM. Facts, rumours and speculations about the mesothelioma epidemic. Respirology DOI: 10.1111/j. 1440-1843.2011.02020.x (2011) (Epub ahead of print).